MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100294-PIP01-21-M01) and to the deferral

MHRA-100294-PIP01-21-M02

Scope of the Application

Active Substance(s)

BENRALIZUMAB

Condition(s)

Treatment of asthma

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

AstraZeneca UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK Limited submitted to the licensing authority on 22/05/2026 16:36 BST an application for a Modification

The procedure started on 02/06/2026 20:15 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100294-PIP01-21-M02

Of 24/06/2026 15:50 BST

On the adopted decision for BENRALIZUMAB (MHRA-100294-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for BENRALIZUMAB, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, UNITED KINGDOM, CB2 0AA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of asthma The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of asthma

2.2 Indication(s) targeted by the PIP:

Add on treatment for uncontrolled asthma with eosinophilic inflammation in children 6 years and older and adolescents (and adults).

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Solution for injection (in pre-filled syringe)

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age appropriate presentation (solution for injection in pre-filled syringe) to ensure that the formulation is able to cover the full range of paediatric doses.
Non-Clinical Studies	0	Not applicable
Clinical Studies	6	Study 2 Multicentre, randomized, double-blind, placebo-controlled 56-week study to evaluate the efficacy and safety of subcutaneous (SC) benralizumab (MEDI-563) in adolescents (and adults) with uncontrolled asthma. Study 3 Multicentre, randomized, double-blind, placebo-controlled 48-week study to evaluate the efficacy and safety of subcutaneous (SC) benralizumab (MEDI-563) in adolescents (and adults) with uncontrolled asthma. Study 4, deleted during procedure MHRA-100294-PIP01-21-M01. Study 5, deleted during procedure MHRA-100294-PIP01-21-M01. Study 6, deleted during procedure MHRA-100294-PIP01-21-M01. Study 7 Randomized, parallel group extension study to establish the long-term safety of two dosing regimens

		of subcutaneous benralizumab in adolescent (and adult) subjects with inadequately controlled asthma. Study 8, deleted during procedure MHRA-100294-PIP01-21-M01. Study 9 Multicentre, randomised, double-blind, parallel group, placebo-controlled study to evaluate the effect of benralizumab on immune responses following seasonal influenza virus vaccination in adolescent patients (and young adults) with asthma. Study 10 (added during procedure MHRA-100294-PIP01-21-M01) Uncontrolled, open-label trial to evaluate safety, tolerability and effect of body weight and age on the pharmacokinetics (PK) of benralizumab, and to assess the relationship between benralizumab exposure and pharmacodynamic (PD) response using blood eosinophils in children from 6 years to less than 12 years with severe asthma Study 13 (added during procedure MHRA-100294-PIP01-21-M01) Randomised, double-blind, placebo-controlled trial, followed by an open-label extension phase to evaluate efficacy and safety of benralizumab in children from 6 years to less than 18 years with severe eosinophilic asthma
Extrapolation, Modeling & Simulation Studies	1	Study 11 (added during procedure MHRA-100294-PIP01-21-M01) Population pharmacokinetic (PK) model and PK/ pharmacodynamic (PD) model to confirm that PK and PD profiles similar to adults are attained in children from 6 years to less than 18 years of age with severe eosinophilic asthma.
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/09/2032

Deferral of one or more studies contained in the paediatric investigation plan:	Yes